Prenatal screening for sex chromosome aneuploidies (SCAs) is increasingly available
through expanded non‐invasive prenatal testing (NIPT). NIPT for SCAs raises complex …

OBJECTIVE Although cell-free DNA screening for sex chromosome abnormalities is
increasingly used in clinical practice, its diagnostic accuracy and clinical utility remain …

Non-invasive prenatal testing (NIPT) for trisomies 21, 18, 13 and monosomy X is widely
utilized with massively parallel shotgun sequencing (MPSS), digital analysis of selected …

Objective This study aimed to assess the utility of chromosomal microarray analysis (CMA)
and noninvasive prenatal testing (NIPT) in detecting clinically significant chromosomal …

The discovery of cell-free fetal DNA (cffDNA) in maternal blood and the rapid development of
massively parallel sequencing have revolutionized prenatal testing from invasive to …

Objectives To evaluate the performance of cell‐free DNA (cfDNA) screening for common
fetal aneuploidies, choice of prenatal procedure, and chromosome conditions identified …

Objective: To assess the association between lipid metabolism and fetal fraction, which is a
critical factor in ensuring a highly accurate non-invasive prenatal testing (NIPT), and on the …

Background This paper evaluated the clinical utility of massively parallel sequencing-based
non-invasive prenatal testing (NIPT) for detecting trisomy 21 (T21), T18, T13, sex …

Objective We aimed to investigate how the presence of fetal anomalies and different X
chromosome variants influences Cell‐free DNA (cfDNA) screening results for monosomy X …

Background: Cell-free NIPT and cell-based NIPT are risk-free testing options using maternal
blood samples to screen for fetal aneuploidies, but the methods differ. For cell-free NIPT, the …